VolitionRx Participates in the 97th Annual Western Veterinary Conference
VolitionRx Limited, a pioneering epigenetics company, is thrilled to announce its attendance at the 97th Annual Western Veterinary Conference (WVC), taking place in Henderson, Nevada. This esteemed event, which attracts around 20,000 veterinary professionals, is one of the largest and longest-running conferences in the United States.
Featured Speakers
Volition’s presence at the conference will include presentations from esteemed veterinarians and industry experts: Dr. Sue Ettinger, DVM, also known as Dr. Sue Cancer Vet; Dr. Brett Cordes, DVM; and Dr. Tom Butera, DVM.
Dr. Sue Ettinger
Dr. Sue Ettinger, DVM, is a renowned veterinary oncologist and an advocate for pet cancer awareness. She is the author of “The Dog Cancer Survival Guide: Full Spectrum Treatments to Optimize Your Dog’s Life Quality and Longevity,” which provides valuable information for pet owners dealing with cancer diagnosis. Her presentation at the WVC is expected to shed light on the latest advancements in veterinary oncology and the role of epigenetics in cancer treatment.
Dr. Brett Cordes
Dr. Brett Cordes, DVM, is a respected veterinarian and a leading expert in the field of veterinary diagnostics. He is the founder and CEO of Cordes Veterinary Consulting, where he provides consultation services to veterinarians and pet owners. Dr. Cordes’ presentation at the WVC will focus on the role of epigenetics in veterinary diagnostics and how it can help improve the accuracy and efficiency of disease detection.
Dr. Tom Butera
Dr. Tom Butera, DVM, is a veterinarian and the Chief Veterinary Officer at VolitionRx. He brings extensive experience in veterinary medicine and has a deep understanding of the company’s epigenetic testing technologies. In his presentation, Dr. Butera will discuss how Volition’s Nu.Q™ technology can be applied to various veterinary applications, including disease detection and monitoring.
Impact on the Veterinary Community
The participation of VolitionRx in the WVC is a significant development for the veterinary community. The company’s epigenetic testing technologies have the potential to revolutionize the way veterinarians diagnose and monitor diseases, ultimately improving animal health and welfare. The presentations from Dr. Sue Ettinger, Dr. Brett Cordes, and Dr. Tom Butera will provide valuable insights into the latest advancements in veterinary oncology, diagnostics, and epigenetics.
Global Implications
Beyond the veterinary community, VolitionRx’s epigenetic testing technologies have the potential to impact human health as well. The company’s Nu.Q™ technology is currently being applied to human diagnostics, and it has shown promise in the early detection of various diseases, including cancer. The insights gained from the veterinary applications of this technology could lead to further advancements in human health diagnostics and treatments.
Conclusion
The attendance of VolitionRx at the 97th Annual Western Veterinary Conference marks an exciting development for the veterinary community. The presentations from Dr. Sue Ettinger, Dr. Brett Cordes, and Dr. Tom Butera will provide valuable insights into the latest advancements in veterinary oncology, diagnostics, and epigenetics. The potential applications of VolitionRx’s epigenetic testing technologies in both veterinary and human health have the power to revolutionize disease detection and monitoring, ultimately improving animal and human health and welfare. Stay tuned for further updates from the WVC and the latest developments from VolitionRx.
- VolitionRx participates in the 97th Annual Western Veterinary Conference
- Presentations from Dr. Sue Ettinger, Dr. Brett Cordes, and Dr. Tom Butera
- Advancements in veterinary oncology, diagnostics, and epigenetics
- Potential applications in human health
- Improvement in animal and human health and welfare
